uniQure N.V. (NASDAQ:QURE) Q4 2025 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kate, and I will be your conference operator today.
Uniqure N.v. (QURE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 6,150,000 | $147,169,500 | +39% | 1.45% |
| 2. | BioImpact Capital Mpm Capital | 1,381,628 | $33,062,358 | 3.78% | |
| 3. | Suvretta Capital Management Aaron Cowen | 1,216,734 | $29,116,445 | 0.6% | |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 1,110,400 | $26,571,872 | +172% | 0.05% |
| 5. | Artia Global Partners Onusa Chantanapongwanij | 1,023,539 | $24,493,288 | +56% | 3.47% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.06 | 14,581 | $132,103.86 | 660,658 | 2026-03-04 | Filing | |
| $9.06 | 808 | $7,320.48 | 189,669 | 2026-03-04 | Filing | |
| $9.06 | 3,412 | $30,912.72 | 138,483 | 2026-03-04 | Filing | |
| $9.06 | 12,000 | $108,720.00 | 226,581 | 2026-03-04 | Filing | |
| $9.95 | 34,437 | $342,648.15 | 604,639 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,240,936 | $149,345,604 | 0.01% | |
| 2. | 3,711,462 | $88,815,286 | 0.89% | |
| 3. | 3,678,640 | $88,029,855 | 0.14% | |
| 4. | 3,231,043 | $77,318,859 | 0% | |
| 5. | 2,934,626 | $70,225,603 | 0% |
News See All
Wolfe Research Initiates Coverage of UniQure (QURE) With a Peer Perform Rating
UniQure (NASDAQ:QURE) is one of the top gene therapy stocks to buy according to hedge funds.
Top 10 Gene Therapy Stocks to Buy According to Hedge Funds
On February 23, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets and tariff uncertainties.
UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity
UniQure (NASDAQ:QURE) is one of the most promising low-cost stocks to buy now.
11 Most Promising Low-Cost Stocks to Buy Now
On February 7, Richard Bernstein, CEO of Richard Bernstein Advisors, joined 'The Exchange' on CNBC to discuss the state of equity markets, assessing which stocks are growing fast and trading cheaply.
Here's Why uniQure (QURE) Declined in Q4
Apis Capital Advisors’ Apis Flagship Fund released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
Here’s Why uniQure (QURE) Fell in Q3
Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Is UniQure (QURE) One of the Promising Stocks to Buy Under $50?
UniQure (NASDAQ:QURE) is one of the promising stocks to buy under $50.
10 Promising Stocks to Buy Under $50
On January 7, Jay Woods, Chief Market Strategist at Freedom Capital Markets, joined CNBC to state that stocks are broadening beyond tech, with materials, defense, transports, and airlines showing breakouts...
What Do Analysts Think About UniQure (QURE)?
UniQure (NASDAQ:QURE) is one of the best small cap stocks to buy with huge upside potential.
Hedge Fund Resource Center